Eli Lilly Agrees to Acquire Calytrix Bio in Deal Worth Up to $1.5 Billion
Eli Lilly announced it will acquire Calytrix Bio, a privately held biotech backed by JPMorgan Chase, in a deal valued at up to $1.5 billion. Calytrix is developing treatments targeting a set of rare blood cancers.